WealthPLAN Partners LLC Grows Stake in Allergan plc (AGN)

WealthPLAN Partners LLC grew its holdings in shares of Allergan plc (NYSE:AGN) by 16.6% in the 1st quarter, Holdings Channel reports. The firm owned 14,171 shares of the company’s stock after purchasing an additional 2,022 shares during the quarter. WealthPLAN Partners LLC’s holdings in Allergan were worth $2,385,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AGN. Prosight Management LP purchased a new stake in Allergan in the 4th quarter worth approximately $16,031,000. Tower Research Capital LLC TRC increased its holdings in Allergan by 479.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after acquiring an additional 1,463 shares in the last quarter. Canyon Capital Advisors LLC increased its holdings in Allergan by 248.4% in the 4th quarter. Canyon Capital Advisors LLC now owns 501,494 shares of the company’s stock worth $82,034,000 after acquiring an additional 357,559 shares in the last quarter. Vantage Financial Partners Ltd. Inc. increased its holdings in Allergan by 23.8% in the 4th quarter. Vantage Financial Partners Ltd. Inc. now owns 6,250 shares of the company’s stock worth $1,018,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Stephens Inc. AR increased its holdings in Allergan by 24.2% in the 1st quarter. Stephens Inc. AR now owns 30,566 shares of the company’s stock worth $5,144,000 after acquiring an additional 5,960 shares in the last quarter. 79.43% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently issued reports on the stock. Piper Jaffray Companies set a $161.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Thursday, May 31st. JPMorgan Chase & Co. set a $265.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Friday, April 27th. Mizuho reissued a “hold” rating and issued a $150.00 target price on shares of Allergan in a report on Wednesday, May 30th. Finally, Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $183.43 target price for the company. in a report on Thursday, March 15th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $212.15.

In other news, EVP William Meury sold 24,425 shares of the stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $154.59, for a total transaction of $3,775,860.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.37% of the stock is currently owned by corporate insiders.

Shares of NYSE AGN traded up $2.56 during midday trading on Thursday, reaching $172.79. 33,955 shares of the stock traded hands, compared to its average volume of 3,119,930. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.10. The company has a market capitalization of $57.99 billion, a P/E ratio of 10.58, a P/E/G ratio of 1.21 and a beta of 1.12. Allergan plc has a one year low of $142.81 and a one year high of $256.80.

Allergan (NYSE:AGN) last posted its earnings results on Monday, April 30th. The company reported $3.74 EPS for the quarter, beating analysts’ consensus estimates of $3.36 by $0.38. The firm had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.35 EPS. equities analysts predict that Allergan plc will post 16.06 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 15th. Stockholders of record on Friday, May 18th will be given a dividend of $0.72 per share. The ex-dividend date is Thursday, May 17th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.67%. Allergan’s dividend payout ratio is currently 17.61%.

Allergan Profile

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply